All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

10

Reset

10 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • TNG462Phase 23 trials

    Tango Therapeutics, Inc. · MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC

  • RDEABSK141-Recommended Expansion, S095018 RecommendedPhase 22 trials

    Abbisko Therapeutics Co, Ltd · Solid Tumors, Adult, Non-small Cell Lung Cancer (NSCLC)

  • S095029Phase 22 trials

    Servier Bio-Innovation LLC · Non-small Cell Lung Cancer (NSCLC), MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer

  • BN104Phase 21 trial

    Institut de Recherches Internationales Servier (I.R.I.S.) · ALL, Adult, AML, Adult, Acute Leukaemia

  • S095018Phase 21 trial

    Servier Bio-Innovation LLC · Non-small Cell Lung Cancer (NSCLC)

  • S095024Phase 21 trial

    Servier Bio-Innovation LLC · Non-small Cell Lung Cancer (NSCLC)

  • S095035Phase 21 trial

    Servier Bio-Innovation LLC · MTAP-deleted Solid Tumors

  • S241656Phase 21 trial

    Servier · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Acute Myeloid Leukemia

  • S243249Phase 21 trial

    Servier · Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia

  • S247240Phase 21 trial

    Institut de Recherches Internationales Servier (I.R.I.S.) · Fragile X Syndrome (FXS)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.